AUS
NZ
UK
CA
USA
IND
Bioxyne Limited (ASX:BXN) has submitted an application to list new ordinary shares following the exercise of options and conversion of convertible securities in late June 2026. The company filed an Appendix 2A to request quotation of shares issued from conversions under ASX codes BXNAF and BXNAE, with these securities issued on 24 June 2026. This development highlights continued engagement by holders of the company’s existing option and convertible security series, and investors will be monitoring for further conversions since not all securities have yet been exercised or converted.
Key Points
- Company: Bioxyne Limited (ASX:BXN)
- Application made for quotation of new ordinary shares resulting from option exercises and convertible security conversions (BXNAF and BXNAE)
- Conversions included 600 BXNAF securities and 873,890 BXNAE securities between 19 June and 24 June 2026 — post-consolidation figures
- New shares were issued on 24 June 2026
- Remaining BXNAF and BXNAE securities have not yet been exercised or converted, indicating potential for further share issuance
- Investors should watch for additional Appendix 2A or Appendix 3H filings related to the cessation of outstanding securities
Bioxyne Files for ASX Quotation of Shares Issued on 24 June 2026
Bioxyne Limited has officially applied to the Australian Securities Exchange for quotation of a new batch of ordinary shares, lodging an Appendix 2A form concerning shares issued on 24 June 2026. This application is a routine procedural requirement under ASX Listing Rules when new securities arise from option exercises or convertible security conversions. Upon approval, these shares will be tradable on the ASX alongside the company’s existing ordinary shares.
The filing confirms the shares were issued on 24 June 2026, aligning with the conversion period disclosed in the form, spanning 19 June to 24 June 2026. The submission is categorized as a new announcement rather than an amendment or cancellation, indicating this is the initial quotation request for this tranche of shares.
Conversions of BXNAF and BXNAE Securities Lead to New Share Issuance
The shares applied for quotation stem from the exercise and conversion of securities under ASX codes BXNAF and BXNAE. The company’s update reports 600 BXNAF securities and 873,890 BXNAE securities converted, both figures reflecting post-consolidation numbers. This distinction is important for investors evaluating the volume of new shares entering the market.
The presence of two security classes, BXNAF and BXNAE, indicates multiple series of convertible instruments are outstanding. Conversion of these instruments into ordinary shares is a standard process allowing holders to realize equity. The filing does not detail the specific terms, exercise prices, or expiry conditions of these series; investors should consult prior disclosures for those details.
Post-Consolidation Figures Reflect Previous Capital Structure Adjustments
The reference to "post consolidation" confirms Bioxyne previously conducted a share consolidation, combining shares at a set ratio to reduce the total number on issue. Such actions typically aim to increase per-share prices and simplify capital structure. The conversion figures are thus presented relative to the company’s adjusted share base, not pre-consolidation levels.
The filing does not specify the consolidation ratio, completion date, or total shares outstanding after these conversions. Investors seeking comprehensive capital structure details should review earlier announcements covering the consolidation event.
Conversion Period Spanned 19 to 24 June 2026
The options and convertible securities were exercised and converted over five days, from 19 June to 24 June 2026. This clustered timing, culminating in the 24 June issuance, suggests multiple conversions occurred within a short timeframe rather than a single transaction. The Appendix 2A was promptly lodged following issuance, consistent with Bioxyne’s continuous disclosure obligations.
The timing may correspond to an approaching expiry of these securities, although this is not confirmed in the filing. Investors tracking Bioxyne’s capital management should note the company’s commitment to timely market notifications of such events.
Outstanding BXNAF and BXNAE Securities Remain Post-June Conversions
The filing reveals that not all BXNAF and BXNAE securities have been exercised or converted, with some still outstanding. This means further share issuances could occur if holders convert remaining instruments, a key consideration for investors monitoring potential dilution.
Under ASX Listing Rules, if any remaining options or convertible securities expire unexercised or are cancelled, Bioxyne must lodge an Appendix 3H to notify the market of their cessation. The current filing acknowledges this possibility. The exact number of outstanding BXNAF and BXNAE securities after June conversions was not disclosed.
Impact of Option Exercises on Bioxyne’s Ordinary Shares
Option exercises and convertible security conversions are common methods for listed companies to increase ordinary shares without new capital raises. In this case, conversion of 873,890 BXNAE and 600 BXNAF securities (post-consolidation) increases Bioxyne’s ordinary shares accordingly. This may modestly dilute earnings per share depending on the company’s total issued capital.
The filing does not disclose any proceeds received from option exercises or conversion prices. Investors interested in the financial impact should monitor future financial reports or quarterly activity statements for further information.
Corporate Identification Details Confirmed in Quotation Application
The Appendix 2A confirms Bioxyne Limited’s full legal name and Australian Business Number (ABN) 97 084 464 193. The company operates under ASX issuer code BXN. These details formally identify the issuer within ASX securities administration.
As an Australian-registered entity, Bioxyne’s shares are denominated in Australian dollars and traded domestically on the ASX under ticker BXN. This quotation application is therefore a standard domestic process under ASX Listing Rules.
Outlook: Monitoring Further Conversions and Potential Appendix 3H Filings
With remaining BXNAF and BXNAE securities still outstanding, investors should watch for additional exercises or conversions before expiry. Each such event would prompt a new Appendix 2A application to quote newly issued shares, potentially increasing Bioxyne’s share count further.
If any remaining securities lapse, expire, or are cancelled without conversion, Bioxyne is expected to file an Appendix 3H to inform the market, as noted in the current filing. Updates to total securities on issue will also be reflected in quarterly Appendix 4C or 5B reports and future capital management announcements.
Market Impact and Context of the Share Issuance
The immediate effect on Bioxyne’s share price is unclear from public information. The conversion of 600 BXNAF securities is unlikely to materially affect capital structure alone, while the 873,890 BXNAE conversions represent a more significant addition depending on total shares outstanding. Market participants will assess the issuance’s significance relative to Bioxyne’s overall capitalization.
This filing is an administrative step related to quoting already-issued shares and does not represent a new fundraising, strategic update, or business development. Investors seeking operational or financial information should refer to Bioxyne’s latest quarterly reports, investor presentations, and other ASX disclosures.
